37517-28-5
Chemical Structure
Amikacin
Synonym(s): BAY 41-6551
- CAS No.: 37517-28-5
- Formula:C22H43N5O13
- Molecular Weight:585.60
IUPAC Name: (S)-4-amino-N-((1R,2S,3S,4R,5S)-5-amino-2-(((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4-(((2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-3-hydroxycyclohexyl)-2-hydroxybutanamide
InChIKey: LKCWBDHBTVXHDL-RMDFUYIESA-N
SMILES: O[C@@H]1[C@H]([C@@H](C[C@H](N)[C@H]1O[C@@]([C@@H]([C@@H](O)[C@@H]2O)O)([H])O[C@@H]2CN)NC([C@@H](O)CCN)=O)O[C@@]([C@@H]([C@@H](N)[C@@H]3O)O)([H])O[C@@H]3CO
Biological Activity: Amikacin (BAY 41-6551) is a semisynthetic kanamycin analog that is active against most Gram-negative bacteria, including gentamicin- and tobramycin-resistant strains. Significant inhibitory effect. Amikacin is ototoxic and nephrotoxic. Amikacin can be used in bacteriostatic, anti-cancer and analgesic studies[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Amikacin | 99.92% | Amikacin (BAY 41-6551) is a semisynthetic kanamycin analog that is active against most Gram-negative bacteria, including gentamicin- and tobramycin-resistant strains. Significant inhibitory effect. Amikacin is ototoxic and nephrotoxic. Amikacin can be used in bacteriostatic, anti-cancer and analgesic studies. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Amikacin (Standard) | 97.58% | Amikacin (Standard) is the analytical standard of Amikacin. This product is intended for research and analytical applications. Amikacin (BAY 41-6551), a semisynthetic analog of kanamycin, is very active against most gram-negative bacteria including gentamicin- and tobramycin-resistant strains. Amikacin (BAY 41-6551) is ototoxic and nephrotoxic. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Farhan SM, et al. In Vitro and In Vivo Effect of Amikacin and Imipenem Combinations against Multidrug-Resistant E. coli. Trop Med Infect Dis. 2022 Oct 2;7(10):281. [Content Brief]
- [2]. Wang YH, et al. Amikacin Suppresses Human Breast Cancer Cell MDA-MB-231 Migration and Invasion. Toxics. 2020 Nov 20;8(4):108. [Content Brief]
- [3]. Atamer-Simsek S, et al. Antinociceptive effect of amikacin and its interaction with morphine and naloxone. Pharmacol Res. 2000 Mar;41(3):355-60. [Content Brief]
- [4]. Ladrech S, et al. Calpain activity in the amikacin-damaged rat cochlea. J Comp Neurol. 2004 Sep 13;477(2):149-60. [Content Brief]
- [5]. Chan K, et al. Characterization of Amikacin Drug Exposure and Nephrotoxicity in an Animal Model. Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00859-20. [Content Brief]
